Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact

Boston Scientific (BSX) fell 5.81% to $42.44 after cutting Q4 and full-year guidance due to a cyberattack. The company reported 1.5% sales growth and $0.73 adjusted EPS for Q3, missing estimates. Management expects a slow recovery, with 3.75% sales growth projected for 2026. Trading volume was 66.8M shares, 234% above average. The S&P 500 and Nasdaq Composite both rose slightly.

Original reporting
Published Oct 28, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact — source image
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The guidance cut is likely to keep the stock under pressure until tangible progress on the cyber recovery and acquisition integration is shown.

02

Market read

New guidance cut for a mid‑cap medical‑device firm, immediate price impact and sector‑wide risk considerations.

03

What to watch

Potential upside from the pending Penumbra acquisition and long‑term growth investments.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Boston Scientific disclosed that an eight‑day cyberattack reduced sales growth by 300 bps and EPS by $0.07, prompting a lower guidance.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific cut Q4 and full-year EPS guidance after a cyberattack, causing a 6% share drop.

Expected impact

downward pressure as investors price in lower sales and EPS forecasts

Evidence & confidence

The guidance reduction is a fresh, material fact and the stock already fell 6% on the news.

Market effects

Medical‑device peers may face heightened scrutiny of cyber risk and guidance outlook.

U.S. equity markets could see modest drag in the healthcare sector.

Limited to U.S. listed medical‑device companies.

Counterpoint

If the Penumbra integration succeeds, BSX could rebound despite short‑term guidance weakness.

Key entities

  • Boston Scientific

    Medical‑device maker reporting guidance cut.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.